Sustained-release preparation for AII antagonist, production and use thereof

1. An injectable sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or its salt, and a biodegradable polymer, wherein said compound having angiotensin II antagonistic activity is a compound

selected from the group consisting of 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid, 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and 2-ethoxy-1-[[2′-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid,

and is formulated as an injectable sustained release preparation.

2. A sustained-release preparation according to claim 1 , wherein the compound having angiotensin II antagonistic activity is 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or a salt thereof.

3. A sustained-release preparation according to claim 1 , wherein the compound having angiotensin II antagonistic activity is 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate or a salt thereof.

4. A sustained-release preparation according to claim 1 , wherein the compound having angiotensin II antagonistic activity is 2-ethoxy-1-[[2′-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or a salt thereof.

5. A sustained-release preparation according to claim 1 , wherein the biodegradable polymer is α-hydroxycarboxylic acid polymer.

6. A sustained-release preparation according to claim 5 , wherein the α-hydroxycarboxylic acid polymer is lactic acid-glycolic acid polymer.

7. A sustained-release preparation according to claim 6 , wherein the molar ratio of lactic acid and glycolic acid is 100/0-40/60.

8. A sustained-release preparation according to claim 5 , wherein the weight-average molecular weight of the polymer is 3,000-50,000.

9. A sustained-release preparation according to claim 1 , which further comprises a polyvalent metal.

10. A sustained-release preparation according to claim 9 , wherein the polyvalent metal is zinc.

11. An injectable sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or its salt, a biodegradable polymer and a polyvalent metal, wherein said compound having angiotensin II antagonistic activity is a compound

selected from the group consisting of 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid, 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and 2-ethoxy-1-[[2′-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid,

and is formulated as a sustained release preparation for injection.

12. A method for producing the sustained-release preparation as claimed in claim 1 , which comprises removing the solvent from a solution containing a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer.

13. A method for producing a sustained-release preparation as claimed in claim 11 , which comprises removing the solvent from a solution containing a compound having angiotensin II antagonistic activity, its pro-drug or their salt, a biodegradable polymer and a polyvalent metal.

14. A method according to claim 13 , wherein the polyvalent metal is zinc.

15. A pharmaceutical composition comprising the sustained-release preparation as claimed in claim 1 .

16. A composition as claimed in claim 15 , which is for the prevention or treatment of circulatory disease.

17. A composition as claimed in claim 15 , which is for the prevention or treatment of hypertension.

18. A composition as claimed in claim 15 , which is for the prevention or treatment of hypercardia, cardiac insufficiency, myocardial infarction, cerebral apoplexy, ischemic peripheral circulation disturbances, myocardial ischemia, vein insufficiency, progressive cardiac insufficiency after myocardial infarction, diabetic complication, diabetic retinopathy, diabetic nephropathy, nephritis, glomerulonephritis, arteriosclerosis, angiohypertrophy, vascular hypertrophy or obstruction after intervention, vascular reobstruction after bypass surgery, hyperaldosteronism, glomerulosclerosis, renal insufficiency, glaucoma, intraocular high tension, hyperlipemia, angina pectoris, aneurysm, coronary arteriosclerosis, cerebral arteriosclerosis, peripheral arteriosclerosis, thrombosis, disease of central nervous system, Alzheimer's disease, deficiency of memory, depression, amnesia, senile dementia, sensory disturbances, multiple system organ failure, a disease due to endothelial dysfunction or scleroderma, or the prevention or amelioration of anxiety neurosis, catatonia, indisposition or dyspeptic symptoms.